• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑转移瘤切除术后立体定向腔隙照射或全脑放疗——结果、预后因素及复发模式

Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection-Outcome, Prognostic Factors, and Recurrence Patterns.

作者信息

El Shafie Rami A, Dresel Thorsten, Weber Dorothea, Schmitt Daniela, Lang Kristin, König Laila, Höne Simon, Forster Tobias, von Nettelbladt Bastian, Eichkorn Tanja, Adeberg Sebastian, Debus Jürgen, Rieken Stefan, Bernhardt Denise

机构信息

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany.

出版信息

Front Oncol. 2020 May 8;10:693. doi: 10.3389/fonc.2020.00693. eCollection 2020.

DOI:10.3389/fonc.2020.00693
PMID:32477942
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7232539/
Abstract

Following the resection of brain metastases (BM), whole-brain radiotherapy (WBRT) is a long-established standard of care. Its position was recently challenged by the less toxic single-session radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) of the resection cavity, reducing dose exposure of the healthy brain. We analyzed 101 patients treated with either SRS/FSRT ( = 50) or WBRT ( = 51) following BM resection over a 5-year period. Propensity score adjustment was done for age, total number of BM, timepoint of BM diagnosis, controlled primary and extracranial metastases. A Cox Proportional Hazards model with univariate and multivariate analysis was fitted for overall survival (OS), local control (LC) and distant brain control (DBC). Median patient age was 61 (interquartile range, IQR: 56-67) years and the most common histology was non-small cell lung cancer, followed by breast cancer. 38% of the patients had additional unresected BM. Twenty-four patients received SRS, 26 patients received FSRT and 51 patients received WBRT. Median OS in the SRS/FSRT subgroup was not reached (IQR NA-16.7 months) vs. 12.6 months (IQR 21.3-4.4) in the WBRT subgroup (hazard ratio, HR 3.3, 95%-CI: [1.5; 7.2] < 0.002). Twelve-months LC-probability was 94.9% (95%-CI: [88.3; 100.0]) in the SRS subgroup vs. 81.7% (95%-CI: [66.6; 100.0]) in the WBRT subgroup (HR 0.2, 95%-CI: [0.01; 0.9] = 0.037). Twelve-months DBC-probabilities were 65.0% (95%-CI: [50.8; 83.0]) and 58.8% (95%-CI: [42.9; 80.7]), respectively (HR 1.4, 95%-CI: [0.7; 2.7] = 0.401). In propensity score-adjusted multivariate analysis, incomplete resection negatively impacted OS (HR 3.9, 95%-CI: [2.0;7.4], < 0.001) and LC (HR 5.4, 95%-CI: [1.3; 21.9], = 0.018). Excellent clinical performance (HR 0.4, 95%-CI: [0.2; 0.9], = 0.030) and better graded prognostic assessment (GPA) score (HR 0.4, 95%-CI: [0.2; 1.0], = 0.040) were prognostic of superior OS. A higher number of BM was associated with a greater risk of developing new distant BM (HR 5.6, 95%-CI: [1.0; 30.4], = 0.048). In subgroup analysis, larger cavity volume (HR 1.1, 95%-CI: [1.0; 1.3], = 0.033) and incomplete resection (HR 12.0, 95%-CI: [1.2; 118.3], = 0.033) were associated with inferior LC following SRS/FSRT. This is the first propensity score-adjusted direct comparison of SRS/FSRT and WBRT following the resection of BM. Patients receiving SRS/FSRT showed longer OS and LC compared to WBRT. Future analyses will address the optimal choice of safety margin, dose and fractionation for postoperative stereotactic RT of the resection cavity.

摘要

脑转移瘤(BM)切除术后,全脑放疗(WBRT)一直是既定的标准治疗方法。最近,其地位受到了切除腔单次立体定向放射外科治疗(SRS)或分次立体定向放射治疗(FSRT)的挑战,后者毒性较小,可减少健康脑组织的剂量暴露。我们分析了5年间101例BM切除术后接受SRS/FSRT(n = 50)或WBRT(n = 51)治疗的患者。对年龄、BM总数、BM诊断时间点、原发灶及颅外转移灶的控制情况进行了倾向评分调整。采用Cox比例风险模型进行单因素和多因素分析,以评估总生存期(OS)、局部控制率(LC)和远处脑转移控制率(DBC)。患者中位年龄为61岁(四分位间距,IQR:56 - 67岁),最常见的组织学类型为非小细胞肺癌,其次为乳腺癌。38%的患者有额外未切除的BM。24例患者接受SRS治疗,26例患者接受FSRT治疗,51例患者接受WBRT治疗。SRS/FSRT亚组的中位OS未达到(IQR NA - 16.7个月),而WBRT亚组为12.6个月(IQR 21.3 - 4.4)(风险比,HR 3.3,95%置信区间:[1.5;7.2],P < 0.002)。SRS亚组的12个月LC概率为94.9%(95%置信区间:[88.3;100.0]),WBRT亚组为81.7%(95%置信区间:[66.6;100.0])(HR 0.2,95%置信区间:[0.01;0.9],P = 0.037)。12个月的DBC概率分别为65.0%(95%置信区间:[50.8;83.0])和58.8%(95%置信区间:[42.9;80.7])(HR 1.4,95%置信区间:[0.7;2.7],P = 0.401)。在倾向评分调整的多因素分析中,不完全切除对OS(HR 3.9,95%置信区间:[2.0;7.4],P < 0.001)和LC(HR 5.4,95%置信区间:[1.3;21.9],P = 0.018)有负面影响。良好的临床表现(HR 0.4,95%置信区间:[0.2;0.9],P = 0.030)和较好的预后分级评估(GPA)评分(HR 0.4,95%置信区间:[0.2;1.0],P = 0.040)是OS较好的预后因素。较高数量的BM与发生新的远处BM的风险增加相关(HR 5.6,95%置信区间:[1.0;30.4],P = 0.048)。在亚组分析中,较大的腔体积(HR 1.1,95%置信区间:[1.0;1.3],P = 0.033)和不完全切除(HR 12.0,95%置信区间:[1.2;118.3],P = 0.033)与SRS/FSRT后的LC较差相关。这是BM切除术后SRS/FSRT与WBRT的首次倾向评分调整直接比较。与WBRT相比,接受SRS/FSRT的患者OS和LC更长。未来的分析将探讨切除腔术后立体定向放疗安全边缘、剂量和分割的最佳选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/efe44e4762e7/fonc-10-00693-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/89bab0e912e5/fonc-10-00693-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/8f11635959bf/fonc-10-00693-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/aa0dd8b84f1b/fonc-10-00693-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/efe44e4762e7/fonc-10-00693-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/89bab0e912e5/fonc-10-00693-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/8f11635959bf/fonc-10-00693-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/aa0dd8b84f1b/fonc-10-00693-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e874/7232539/efe44e4762e7/fonc-10-00693-g0004.jpg

相似文献

1
Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection-Outcome, Prognostic Factors, and Recurrence Patterns.脑转移瘤切除术后立体定向腔隙照射或全脑放疗——结果、预后因素及复发模式
Front Oncol. 2020 May 8;10:693. doi: 10.3389/fonc.2020.00693. eCollection 2020.
2
A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases.一项配对分析比较了立体定向放射外科与全脑放疗治疗多发脑转移瘤患者的效果。
J Neurooncol. 2020 May;147(3):607-618. doi: 10.1007/s11060-020-03447-2. Epub 2020 Apr 1.
3
Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.单发至三发脑转移患者立体定向放疗后行手术腔定期磁共振成像随访的影响。
Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x.
4
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.基于直线加速器的立体定向放射外科治疗5个或更多放射性抵抗性黑色素瘤脑转移瘤的潜在作用。
J Neurosurg. 2015 Nov;123(5):1261-7. doi: 10.3171/2014.12.JNS141919. Epub 2015 Jul 3.
5
Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases.对于多达十个脑转移瘤的患者,基于直线加速器的分次立体定向放疗和立体定向放射外科的可行性。
Radiat Oncol. 2022 Dec 28;17(1):213. doi: 10.1186/s13014-022-02185-1.
6
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.术后立体定向放射外科与全脑放疗治疗脑转移瘤切除术(NCCTG N107C/CEC·3):一项多中心、随机、对照、3期试验
Lancet Oncol. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4.
7
Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone.辅助性放射治疗对切除的脑转移瘤的颅内控制及影像学改变:全脑放疗与单纯立体定向放射外科治疗的比较
J Neurooncol. 2014 Dec;120(3):657-63. doi: 10.1007/s11060-014-1601-4. Epub 2014 Sep 5.
8
Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control.早期对切除的脑转移瘤瘤床进行伽玛刀立体定向放射外科治疗以改善局部控制。
J Neurosurg. 2014 Dec;121 Suppl:69-74. doi: 10.3171/2014.7.GKS141488.
9
Clinical outcomes of patients treated with a second course of stereotactic radiosurgery for locally or regionally recurrent brain metastases after prior stereotactic radiosurgery.接受立体定向放射外科治疗后局部或区域性复发性脑转移瘤患者的第二疗程立体定向放射外科治疗的临床结果。
J Neurooncol. 2013 Oct;115(1):37-43. doi: 10.1007/s11060-013-1191-6. Epub 2013 Jun 28.
10
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.全脑放疗后行立体定向放射外科治疗复发性脑转移瘤患者的生存预后因素分析。
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11.

引用本文的文献

1
Factors associated with the local control of brain metastases: a systematic search and machine learning application.与脑转移瘤局部控制相关的因素:系统搜索和机器学习应用。
BMC Med Inform Decis Mak. 2024 Jun 21;24(1):177. doi: 10.1186/s12911-024-02579-z.
2
Cytoreduction of Residual Tumor Burden Is Decisive for Prolonged Survival in Patients with Recurrent Brain Metastases-Retrospective Analysis of 219 Patients.降低残留肿瘤负荷对复发性脑转移患者的长期生存至关重要——219例患者的回顾性分析
Cancers (Basel). 2023 Oct 20;15(20):5067. doi: 10.3390/cancers15205067.
3
Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.

本文引用的文献

1
The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.胶质母细胞瘤治疗中的细胞外基质与生物相容性材料
Front Bioeng Biotechnol. 2019 Nov 19;7:341. doi: 10.3389/fbioe.2019.00341. eCollection 2019.
2
Pre-Operative Versus Post-Operative Radiosurgery of Brain Metastases-Volumetric and Dosimetric Impact of Treatment Sequence and Margin Concept.脑转移瘤术前与术后放射外科治疗——治疗顺序和边缘概念的体积和剂量学影响
Cancers (Basel). 2019 Mar 1;11(3):294. doi: 10.3390/cancers11030294.
3
Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis.
颅内术中放疗(IORT):脑电图评估和围手术期癫痫发作风险。
J Neurooncol. 2023 Sep;164(2):423-430. doi: 10.1007/s11060-023-04443-y. Epub 2023 Sep 5.
4
Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.立体定向放射治疗(HFSRT)与单次立体定向放射外科(SRS)治疗脑转移瘤切除术后切除腔(SATURNUS):一项随机 III 期试验的研究方案。
BMC Cancer. 2023 Jul 29;23(1):709. doi: 10.1186/s12885-023-11202-9.
5
Opportunities and Alternatives of Modern Radiation Oncology and Surgery for the Management of Resectable Brain Metastases.现代放射肿瘤学和外科手术在可切除脑转移瘤治疗中的机遇与选择
Cancers (Basel). 2023 Jul 19;15(14):3670. doi: 10.3390/cancers15143670.
6
Resection cavity dynamics and optimal timing of adjuvant stereotactic radiosurgery for resected brain metastases.切除腔动力学与切除后脑转移瘤辅助立体定向放射外科治疗的最佳时机
J Radiosurg SBRT. 2022;8(4):247-255.
7
What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery.假设:对切除腔立体定向放射外科进行回顾性重建,以模拟新辅助立体定向放射外科。
Front Oncol. 2023 Mar 16;13:1056330. doi: 10.3389/fonc.2023.1056330. eCollection 2023.
8
The oligometastatic paradigm and the role of radiotherapy.寡转移瘤范式与放射治疗的作用。
Clin Med (Lond). 2023 Jan;23(1):61-64. doi: 10.7861/clinmed.2022-0559.
9
The Impact of Postoperative Tumor Burden on Patients With Brain Metastases.术后肿瘤负荷对脑转移瘤患者的影响。
Front Oncol. 2022 May 4;12:869764. doi: 10.3389/fonc.2022.869764. eCollection 2022.
10
Whole-Brain Radiotherapy vs. Localized Radiotherapy after Resection of Brain Metastases in the Era of Targeted Therapy: A Retrospective Study.靶向治疗时代脑转移瘤切除术后全脑放疗与局部放疗的比较:一项回顾性研究
Cancers (Basel). 2021 Sep 20;13(18):4711. doi: 10.3390/cancers13184711.
软脑膜癌病姑息性全脑脊髓照射后的结局及预后因素
Cancer Manag Res. 2019 Jan 17;11:789-801. doi: 10.2147/CMAR.S182154. eCollection 2019.
4
Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response.柔脑膜癌病的姑息性放射治疗——疗效、预后因素及症状反应分析
Front Oncol. 2019 Jan 8;8:641. doi: 10.3389/fonc.2018.00641. eCollection 2018.
5
Preoperative stereotactic radiosurgery before planned resection of brain metastases: updated analysis of efficacy and toxicity of a novel treatment paradigm.在计划切除脑转移瘤之前进行术前立体定向放射外科治疗:一种新型治疗模式的疗效和毒性的最新分析
J Neurosurg. 2018 Dec 14;131(5):1387-1394. doi: 10.3171/2018.7.JNS181293. Print 2019 Nov 1.
6
Postoperative local fractionated radiotherapy for resected single brain metastases.术后局部分割放疗治疗切除的单发脑转移瘤。
Strahlenther Onkol. 2018 Dec;194(12):1163-1170. doi: 10.1007/s00066-018-1368-1. Epub 2018 Sep 14.
7
Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED.术后低分割立体定向脑放疗(HSRT)治疗脑转移瘤:更高 BED 可提高局部控制率。
J Neurooncol. 2018 Sep;139(2):449-454. doi: 10.1007/s11060-018-2885-6. Epub 2018 May 10.
8
Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases.多中心分析脑转移瘤患者立体定向放疗的切除腔。
Cancer Med. 2018 Jun;7(6):2319-2327. doi: 10.1002/cam4.1477. Epub 2018 Apr 25.
9
Evaluation of Stereotactic Radiotherapy of the Resection Cavity After Surgery of Brain Metastases Compared to Postoperative Whole-Brain Radiotherapy (ESTRON)-A Single-Center Prospective Randomized Trial.脑转移瘤手术后立体定向放疗与全脑放疗(ESTRON)的对比评价:一项单中心前瞻性随机试验。
Neurosurgery. 2018 Sep 1;83(3):566-573. doi: 10.1093/neuros/nyy021.
10
Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases.脑转移术后完全切除空腔立体定向放射外科的共识勾画指南。
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):436-442. doi: 10.1016/j.ijrobp.2017.09.047. Epub 2017 Oct 4.